Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection

被引:75
作者
Saha, Srishti [1 ]
Mara, Kristin [2 ]
Pardi, Darrell S. [1 ]
Khanna, Sahil [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Adverse Event; Diarrhea; Microbiome; Abdominal Pain; Outcome; HEALTH;
D O I
10.1053/j.gastro.2021.01.010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Fecal microbiota transplantation (FMT) is highly effective for treating recurrent Clostridioides difficile infection (CDI), with emerging data on intermediate and long-term safety. METHODS: A prospective survey-based study was conducted (September 2012-June 2018) in patients undergoing FMT for recurrent CDI. Data on demographics and comorbidities were abstracted from medical records. Patients were contacted at 1 week, 1 month, 6 months, 1 year (short-term), and >= 2 years post-FMT (long-term). Symptoms and new medical diagnoses were recorded at each time point. Data were weighted to account for survey nonresponse bias. Multivariate logistic regression models for adverse events were built using age (per 10-year increment), sex, time of survey, and comorbidities. P < .05 was considered statistically significant. RESULTS: Overall, 609 patients underwent FMT; median age was 56 years (range, 18-94), 64.8% were women, 22.8% had inflammatory bowel disease (IBD). At short-term follow-up (n = 609), >60% of patients had diarrhea and 19%-33% had constipation. At 1 year, 9.5% reported additional CDI episodes. On multivariable analysis, patients with IBD, dialysis-dependent kidney disease, and multiple FMTs had higher risk of diarrhea; risk of constipation was higher in women and lower in IBD (all P < .05). For long-term follow-up (n = 447), median time of follow-up was 3.7 years (range, 2.0-6.8). Overall, 73 new diagnoses were reported: 13% gastrointestinal, 10% weight gain, 11.8% new infections (all deemed unrelated to FMT). Median time to infections was 29 months (range, 0-73) post-FMT. CONCLUSION: FMT appears safe with low risk of transmission of infections. Several new diagnoses were reported, which should be explored in future studies.
引用
收藏
页码:1961 / +
页数:12
相关论文
共 18 条
[1]   Weight Gain After Fecal Microbiota Transplantation [J].
Alang, Neha ;
Kelly, Colleen R. .
OPEN FORUM INFECTIOUS DISEASES, 2015, 2 (01)
[2]   Fecal Microbiota Transplant From a Rational Stool Donor Improves Hepatic Encephalopathy: A Randomized Clinical Trial [J].
Bajaj, Jasmohan S. ;
Kassam, Zain ;
Fagan, Andrew ;
Gavis, Edith A. ;
Liu, Eric ;
Cox, I. Jane ;
Kheradman, Raffi ;
Heuman, Douglas ;
Wang, Jessica ;
Gurry, Thomas ;
Williams, Roger ;
Sikaroodi, Masoumeh ;
Fuchs, Michael ;
Alm, Eric ;
John, Binu ;
Thacker, Leroy R. ;
Riva, Antonio ;
Smith, Mark ;
Taylor-Robinson, Simon D. ;
Gillevet, Patrick M. .
HEPATOLOGY, 2017, 66 (06) :1727-1738
[3]   Long-Term Follow-Up of Colonoscopic Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection [J].
Brandt, Lawrence J. ;
Aroniadis, Olga C. ;
Mellow, Mark ;
Kanatzar, Amy ;
Kelly, Colleen ;
Park, Tina ;
Stollman, Neil ;
Rohlke, Faith ;
Surawicz, Christina .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (07) :1079-1087
[4]   Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant [J].
DeFilipp, Zachariah ;
Bloom, Patricia P. ;
Soto, Mariam Torres ;
Mansour, Michael K. ;
Sater, Mohamad R. A. ;
Huntley, Miriam H. ;
Turbett, Sarah ;
Chung, Raymond T. ;
Chen, Yi-Bin ;
Hohmann, Elizabeth L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :2043-2050
[5]  
Food and Drug Administration, 2019, FECAL MICROBIOTA TRA
[6]  
Food and Drug Administration, 2020, FECAL MICROBIOTA TRA
[7]   The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection [J].
Jalanka, J. ;
Hillamaa, A. ;
Satokari, R. ;
Mattila, E. ;
Anttila, V. -J. ;
Arkkila, P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (03) :371-379
[8]   Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial [J].
Johnsen, Peter Holger ;
Hilpusch, Frank ;
Cavanagh, Jorunn Pauline ;
Leikanger, Ingrid Sande ;
Kolstad, Caroline ;
Valle, Per Christian ;
Goll, Rasmus .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (01) :17-24
[9]   Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry [J].
Kelly, Colleen R. ;
Yen, Eugene F. ;
Grinspan, Ari M. ;
Kahn, Stacy A. ;
Atreja, Ashish ;
Lewis, James D. ;
Moore, Thomas A. ;
Rubin, David T. ;
Kim, Alison M. ;
Serra, Sonya ;
Nersesova, Yanina ;
Fredell, Lydia ;
Hunsicker, Dea ;
McDonald, Daniel ;
Knight, Rob ;
Allegretti, Jessica R. ;
Pekow, Joel ;
Absah, Imad ;
Hsu, Ronald ;
Vincent, Jennifer ;
Khanna, Sahil ;
Tangen, Lyn ;
Crawford, Carl, V ;
Mattar, Mark C. ;
Chen, Lea Ann ;
Fischer, Monika ;
Arsenescu, Razvan, I ;
Feuerstadt, Paul ;
Goldstein, Jonathan ;
Kerman, David ;
Ehrlich, Adam C. ;
Wu, Gary D. ;
Laine, Loren .
GASTROENTEROLOGY, 2021, 160 (01) :183-+
[10]  
Khanna S, CLIN INFECT DIS, DOI 1093/cid/ciaa1492